AU2013277294C1 - Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds - Google Patents

Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds Download PDF

Info

Publication number
AU2013277294C1
AU2013277294C1 AU2013277294A AU2013277294A AU2013277294C1 AU 2013277294 C1 AU2013277294 C1 AU 2013277294C1 AU 2013277294 A AU2013277294 A AU 2013277294A AU 2013277294 A AU2013277294 A AU 2013277294A AU 2013277294 C1 AU2013277294 C1 AU 2013277294C1
Authority
AU
Australia
Prior art keywords
triazolo
pyrimidin
thieno
methyl
methoxybenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013277294A
Other languages
English (en)
Other versions
AU2013277294B2 (en
AU2013277294A1 (en
Inventor
Bryan Branstetter
James Breitenbucher
Brian Dyck
Laurent Gomez
Andrew Richard Hudson
Tami Jo Marrone
Marco Peters
Troy Vickers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dart Neuroscience Cayman Ltd
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of AU2013277294A1 publication Critical patent/AU2013277294A1/en
Publication of AU2013277294B2 publication Critical patent/AU2013277294B2/en
Application granted granted Critical
Publication of AU2013277294C1 publication Critical patent/AU2013277294C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2013277294A 2012-06-18 2013-06-18 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds Ceased AU2013277294C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
US61/661,091 2012-06-18
PCT/US2013/046403 WO2013192225A1 (en) 2012-06-18 2013-06-18 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds

Publications (3)

Publication Number Publication Date
AU2013277294A1 AU2013277294A1 (en) 2015-02-05
AU2013277294B2 AU2013277294B2 (en) 2017-04-13
AU2013277294C1 true AU2013277294C1 (en) 2018-02-08

Family

ID=49756458

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013277294A Ceased AU2013277294C1 (en) 2012-06-18 2013-06-18 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
AU2013277298A Ceased AU2013277298B2 (en) 2012-06-18 2013-06-18 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds
AU2017272245A Active AU2017272245B2 (en) 2012-06-18 2017-12-07 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2013277298A Ceased AU2013277298B2 (en) 2012-06-18 2013-06-18 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds
AU2017272245A Active AU2017272245B2 (en) 2012-06-18 2017-12-07 Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds

Country Status (17)

Country Link
US (7) US9499562B2 (enExample)
EP (3) EP3489238B8 (enExample)
JP (2) JP6129960B2 (enExample)
KR (2) KR102191816B1 (enExample)
CN (2) CN104583217B (enExample)
AU (3) AU2013277294C1 (enExample)
BR (2) BR112014031731B1 (enExample)
CA (2) CA2877149C (enExample)
DK (2) DK3489238T3 (enExample)
ES (2) ES2904267T3 (enExample)
IL (2) IL236233A (enExample)
IN (2) IN2015DN00334A (enExample)
MX (2) MX359615B (enExample)
NZ (2) NZ703950A (enExample)
RU (2) RU2653054C2 (enExample)
SG (3) SG11201408395WA (enExample)
WO (2) WO2013192225A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355669E (pt) * 2000-08-10 2012-01-02 Cold Spring Harbor Lab Treino cognitivo aumentado
IN2015DN00334A (enExample) 2012-06-18 2015-06-12 Dart Neuroscience Cayman Ltd
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) * 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
PT3532064T (pt) 2016-10-28 2020-09-03 H Lundbeck As Tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
WO2018125810A1 (en) 2016-12-28 2018-07-05 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
US11066419B2 (en) * 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
CA3051976A1 (en) * 2017-02-23 2018-08-30 Boehringer Ingelheim International Gmbh New medical use of compound iii
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
TW201920188A (zh) 2017-08-10 2019-06-01 美商美國禮來大藥廠 [1,2,4]三唑衍生物
CN111655695B (zh) 2017-11-27 2025-05-27 达特神经科学有限公司 作为pde1抑制剂的取代的呋喃并嘧啶化合物
WO2019197842A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB2575490A (en) 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
JP7543278B2 (ja) 2019-01-07 2024-09-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP4017858A4 (en) * 2019-08-22 2023-09-27 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
GB201914860D0 (en) * 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
EP4389746A3 (en) * 2022-12-21 2024-07-03 Recordati Industria Chimica E Farmaceutica SPA P2x3 receptor antagonists
WO2025024543A1 (en) * 2023-07-24 2025-01-30 Bpgbio, Inc. Tricyclic ube2k modulators and methods for their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153136A1 (en) * 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ−　アクチエンゲゼルシヤフト ２−置換−ｅ−融合−〔１，２，４〕トリアゾロ−〔１，５−Ｃ〕ピリミジン
DE3677445D1 (de) * 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
CA2318920A1 (en) * 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
PT1355669E (pt) 2000-08-10 2012-01-02 Cold Spring Harbor Lab Treino cognitivo aumentado
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
FR2897061B1 (fr) 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
US9255099B2 (en) * 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
AU2008254907A1 (en) 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of identifying genes involved in memory formation using small interfering RNA(siRNA)
CN101809142A (zh) 2007-09-26 2010-08-18 通用电气医疗集团生物科学生物方法公司 三维可用后即弃生物反应器
CN104370920A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
JP5710493B2 (ja) * 2008-12-06 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2576551A4 (en) * 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
IN2015DN00334A (enExample) 2012-06-18 2015-06-12 Dart Neuroscience Cayman Ltd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153136A1 (en) * 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
IL236232A0 (en) 2015-02-01
KR102191816B1 (ko) 2020-12-17
JP2015526395A (ja) 2015-09-10
AU2013277298A1 (en) 2015-02-05
AU2017272245A1 (en) 2018-01-04
JP2015526394A (ja) 2015-09-10
US10092575B2 (en) 2018-10-09
AU2013277294B2 (en) 2017-04-13
HK1208023A1 (en) 2016-02-19
RU2015100213A (ru) 2016-08-10
EP2861603A1 (en) 2015-04-22
EP2861603A4 (en) 2015-11-11
US10376514B2 (en) 2019-08-13
CN104583217B (zh) 2017-11-17
US10105367B2 (en) 2018-10-23
ES2715325T3 (es) 2019-06-03
EP3489238B8 (en) 2022-02-16
MX357320B (es) 2018-07-04
CN104583213A (zh) 2015-04-29
BR112014031731B1 (pt) 2022-12-06
US9175010B2 (en) 2015-11-03
US20160075719A1 (en) 2016-03-17
CA2877146C (en) 2020-10-20
EP2861605B1 (en) 2017-05-03
DK2861603T3 (en) 2019-03-04
SG10201703253XA (en) 2017-06-29
NZ703949A (en) 2016-10-28
US20170209459A1 (en) 2017-07-27
EP3489238B1 (en) 2021-10-13
JP6240180B2 (ja) 2017-11-29
NZ703950A (en) 2016-10-28
KR102087756B1 (ko) 2020-03-12
KR20150063030A (ko) 2015-06-08
CA2877146A1 (en) 2013-12-27
IN2015DN00335A (enExample) 2015-06-12
IL236233A (en) 2016-10-31
HK1208024A1 (en) 2016-02-19
US20130338139A1 (en) 2013-12-19
IL236233A0 (en) 2015-02-01
AU2013277294A1 (en) 2015-02-05
WO2013192229A1 (en) 2013-12-27
CA2877149A1 (en) 2013-12-27
US20160031901A1 (en) 2016-02-04
WO2013192225A1 (en) 2013-12-27
EP2861605A1 (en) 2015-04-22
WO2013192229A8 (en) 2015-09-03
US9533996B2 (en) 2017-01-03
JP6129960B2 (ja) 2017-05-17
MX359615B (es) 2018-10-03
BR112014031730B1 (pt) 2023-05-16
US20190046535A1 (en) 2019-02-14
RU2653054C2 (ru) 2018-05-07
MX2014015737A (es) 2015-09-16
ES2904267T3 (es) 2022-04-04
US9284335B2 (en) 2016-03-15
CN104583217A (zh) 2015-04-29
BR112014031731A2 (pt) 2017-06-27
DK3489238T3 (da) 2022-01-10
BR112014031730A2 (pt) 2017-06-27
AU2013277298B2 (en) 2017-09-07
US20150158885A1 (en) 2015-06-11
MX2014015740A (es) 2015-11-06
SG11201408397SA (en) 2015-01-29
EP2861605A4 (en) 2016-01-13
SG11201408395WA (en) 2015-01-29
EP3489238A1 (en) 2019-05-29
US20170182052A1 (en) 2017-06-29
IN2015DN00334A (enExample) 2015-06-12
AU2017272245B2 (en) 2019-08-29
RU2015100209A (ru) 2016-08-10
IL236232A (en) 2016-10-31
CN104583213B (zh) 2018-10-26
CA2877149C (en) 2021-01-19
RU2659779C2 (ru) 2018-07-04
KR20150063028A (ko) 2015-06-08
EP2861603B1 (en) 2018-12-19
US9499562B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
AU2013277294C1 (en) Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
HK40006641B (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK40006641A (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
HK1208024B (en) 6-benzyl-6h-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (pde-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders
HK1208023B (en) 6-benzyl-6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c] pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c] pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 SEP 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 SEP 2017

MK14 Patent ceased section 143(a) (annual fees not paid) or expired